Macedonian Journal of Medical Sciences
[International, Peer Reviewed]

 

About MJMS

Our policies

MJMS Online

For contributors

Services

Why publish in MJMS?
Editors
Boards
Indexing
Membership 

Editorial & publishing policies
Competing interests policy 
Open access
Open access license

Reviewer guidelines

Online first
Current issue
Journal archive

Online first fact sheet
Free Registration

Guidelines  [pdf]
Online submission
Help for authors
Reviewers of MJMS

Contact

Transliteration
Subscriptions

Advertising
Reprints and permissions
Resources

 

Abstract                                                                         [Full-Text PDF] [Macedonian Abstract] [OnlineFirst Full-Text PDF]

 

Macedonian Journal of Medical Sciences. 2009 Mar 15; 2(1):22-29.

doi:10.3889/MJMS.1857-5773.2009.0037

Basic Science

 

Effects of Rosiglitazone on Metabolic Parameters and Adiponectin Levels in Fructose-Fed Rats

Emilija Atanasovska1, Krume Jakovski1, Elena Kostova1, Aleksandar Petlichkovski2, Chedo Dimitrovski3, Iskra Bitovska3, Igor Kikerkov1, Ognen Petrovski1, Nikola Labachevski1
 

1Institute of Preclinical and Clinical Pharmacology with Toxicology, Faculty of Medicine, University “Ss Kiril and Metodij”, Skopje, Republic of Macedonia; 2Institute of Immunobiology and Human Genetics, Faculty of Medicine, University “Ss Kiril and Metodij”, Skopje, Republic of Macedonia; 3Endocrinology and Metabolic Disorders Clinic, Faculty of Medicine, University “Ss Kiril and Metodij”, Skopje, Republic of Macedonia
 

Aim. To investigate the effect of the peroxisome proliferators-activator receptor gamma agonist, rosiglitazone, on metabolic parameters and adiponectin levels in an animal model of the metabolic syndrome.

Material and methods. Metabolic syndrome was induced in 32 male Wistar rats by adding a fructose in drinking water for 12 weeks. During the last 4 weeks, 16 rats were treated with rosiglitazone (5 mg/kg/day), while the remaining 16 did not receive any medication (fructose group). Another control group consumed standard rat chow and water for 12 weeks.

Results. Chronic fructose administration induced a significant increase in systolic blood pressure (SBP), body weight, serum triglycerides (TG), free fatty acids (FFA), insulin, glucose AUC0-120 (during oral glucose tolerance test) and decreased serum high density lipoprotein (HDL) cholesterol and adiponectin concentrations compared with the control group. Treatment with rosiglitazone over the final 4 weeks reversed these effects and significantly reduced SBP, TG, FFA, insulin concentrations and glucose AUC0-120 compared with the fructose group. In addition, rosiglitazone increased serum levels of adiponectin twofold from 3.44 ± 0.46 to 7.03 ± 1.30 mg/ml.

Conclusion. This study indicates that rosiglitazone treatment improves the components of the metabolic syndrome, which is accompanied with an increase in adiponectin concentrations.

 

Key words: Rosiglitazone; adiponectin; metabolic syndrome; fructose; insulin.

 

Publication of the MJMS is supported by the Macedonian Ministry of Education and Sciences.
Publisher:
Institute of Immunobiology and Human GeneticsSkopje, Republic of Macedonia.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics.
MJMS Print (ISSN 1857-5749) is an international peer-reviewed, Open Access journal published four times per year.
MJMS Online (ISSN 1857-5773) offers free access to all articles at http://www.mjms.ukim.edu.mk/.

Creative Commons Attribution LicenseAll site content, except where otherwise noted, is licensed under a Creative Commons Attribution License.